Dreyling M, et al. - Since patients with follicular lymphoma (FL) who have the progression of disease within 24 months of first-line immunochemotherapy (POD24) have worse overall survival (OS), researchers examined the outcomes with copanlisib in patients with POD24 in the subset of patients with FL. Eligible patients for the subset analysis were those with histologically confirmed FL relapsed after or refractory to ≥2 prior lines of treatment, including rituximab and an alkylating agent or regimen (eg R-CHOP). On days 1, 8 and 15 of a 28-day cycle, copanlisib 60 mg was administered as a 1-hour infusion. According to findings, R-CHOP was the most prevalent first-line therapy and accounted for 39.7% of patients with POD<24 and 38.2% of patients with POD≥24. This exploratory analysis from the CHRONOS-1 study in relapsed or refractory indolent FL patients receiving 2 or more prior therapy lines showed robust responses in patients with high-risk illness as evidenced by the first-line treatment status of POD24. These findings favor copanlisib exploration in earlier treatment lines in conjunction with chemoimmunotherapy. It was noted that treatment-related serious adverse events occurred in 29.8% of patients.